{"id":"W2952131264","doi":"10.1097/01.hs9.0000558648.00957.de","title":"S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Chlorambucil; Internal medicine; Hazard ratio; Adverse effect; Neutropenia; Progression-free survival; Bendamustine; Clinical endpoint; Oncology; Leukemia; Randomized controlled trial; Confidence interval; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001839133,0.0003164119,0.0009415816,0.00009676751,0.00005479909,0.000009114897,0.0002059808,0.0002277658,0.001417275],"category_scores_gemma":[0.0002728731,0.0002608434,0.000406948,0.0003233656,0.0001226226,0.00008761061,0.00008996471,0.00008644443,0.0001684886],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.05752987,"about_ca_system_score_gemma":0.01560911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007247493,"about_ca_topic_score_gemma":0.0002138356,"domain_scores_codex":[0.9974713,0.00003722597,0.0007235429,0.0005163992,0.0006342647,0.000617283],"domain_scores_gemma":[0.997673,0.0005103807,0.0003053133,0.0009153064,0.0003957951,0.0002001728],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06780622,0.00964883,0.289286,0.08562955,0.010576,0.0003322294,0.02620728,0.02933939,0.03259299,0.004047582,0.05145607,0.3930779],"study_design_scores_gemma":[0.5797849,0.03418195,0.01331924,0.004770201,0.001180009,0.00008260559,0.001371659,0.1703848,0.1521685,0.0004402977,0.04098172,0.001334149],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919594,0.001183224,0.0001314512,0.00003455254,0.0003771155,0.002285256,0.0000755583,0.0000509526,0.003902509],"genre_scores_gemma":[0.9819427,0.0003690307,0.000746652,0.0000231804,0.0001928873,0.0001117174,0.0001532265,0.00008179917,0.0163788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5119786,"threshold_uncertainty_score":0.9999844,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02183908616843046,"score_gpt":0.287915697708241,"score_spread":0.2660766115398106,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}